One month to go for IMI call 11 deadline – Tips for success
12.03.14
As with so many things in life, it’s all about the details: Read the application requirements carefully and make sure all points in the topic text are addressed. That said, there are a few hints we can share in what makes for a successful application. Here, some points to consider:
- Carefully read the call text and guidance document;
- If you are managing a consortium, make sure that your team and application address all the points set out in the topic text;
- Use the IMI Partnering tool to identify consortia working in this field;
- Contact IMI office if you have any questions;
- Read the advice and tips found here to avoid the most common mistakes.
Call 11 covers a range of topics and challenges, addressing some of the areas of high societal need in the EU, including Alzheimer’s, osteoarthritis, and personalised tumour therapy. Another topic addressed is anti-microbial resistance, specifically gram-negative bacteria – an increasingly important issue not only in Europe but also at global level. A full list of topics is available here.
We have already seen some great success stories from IMI and I expect to see more from Call 11. Take a look, for instance, at U-BIOPRED, which explores personalised approaches to severe asthma – or the NEWMEDS project, which has created the largest known database of studies on schizophrenia which make it possible to improve clinical trials amongst others. More inspiration can be found from the DIRECT project, which is advancing personalised therapies in Diabetes, and PharmaCog, a project devoted to developing new tools to test candidate drugs for Alzheimer’s.
What underpins the success of many of these projects is a collaborative spirit – something that defines IMI, a public-private partnership between the European Commission and EFPIA, as a whole.
I hope you are inspired to join this collaboration, and look into IMI Call 11 to see if there is a topic area where you can apply. I look forward to seeing what you and others will bring to contribute to future IMI success stories.
